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Abstract Prostate cancermetastasis to the boneoccurs at high frequency inpatientswith advanceddisease, causing
significantmorbidity andmortality.Over a century ago, the ‘‘seed and soil’’ theorywas proposed to explain organ-specific
patterns of metastases. Today, this theory continues to be relevant as we continue to discover factors involved in the
attraction and subsequent growth of prostate cancer cells to the bone. These include the accumulation of genetic changes
within cancer cells, the preferential binding of cancer cells to bonemarrowendothelial cells, and the release of cancer cell
chemoattractants frombone elements. A keymediator throughout thismetastatic process is the integrin family of proteins.
Alterations in integrin expression and function promote dissociation of cancer cells from the primary tumor mass and
migration into the blood stream.Once in circulation, integrins facilitate cancer cell survival through interactions between
other cancer cells, platelets, and endothelial cells of the target bone. Furthermore, dynamic changes in integrins and in
integrin-associated signal transductionaid in the extravasationof cancer cells into theboneand in expansion to a clinically
relevant metastasis. Thus, we will review the critical roles of integrins in the process of prostate cancer bone metastasis,
from the escape of cancer cells from the primary tumor, to their survival in the harsh ‘‘third microenvironment’’ of the
circulation, and ultimately to their attachment and growth at distant bone sites. J. Cell. Biochem. 91: 706–717, 2004.
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Prostate cancer is the second most common
cause of cancer-related deaths among men in
the United States [Jemal et al., 2003]. It is esti-
mated that 220,900 new cases will be diagnosed
and 28,900 deaths will occur in 2003. Approxi-
mately 90% of advanced stage prostate cancer
patients develop bone lesions causing morbidity
that includes bone pain, immobility, hemato-
poietic compromises, and spinal cord compres-
sion [Bubendorf et al., 2000; Rubin et al., 2000].
Current treatments are not curative, and pa-
tients have a median survival time of 9–
12 months after becoming hormone refractory
[Cheville et al., 2002].
Ellis et al. [2003] reported that prostate-
specific antigen- (PSA-) expressing epithelial
cells were detected in bone marrow samples
from 60 of 126 (54%) patients with localized
prostate cancer before radical prostatectomy,
while only 33 of 138 (24%) patients had de-
tectable PSA-expressing epithelial cells in per-
ipheral blood. This finding supports the
preferential enrichment of cancer cells in the
bone marrow as an early metastatic event and
leads to many interesting questions pertinent to
prostate cancer metastasis. How do the cancer
cells outgrow and escape from the primary site?
How do they survive shear forces present in the
circulation and evade immunosurveillance?
How do these cells interact with the target bone
endothelium? What factors in the bone micro-
environment attract prostate cancer cells and
prompt them to initiate growth? Understanding
the biological processes leading to the establish-
ment of clinically relevant bone metastases is
not just an intellectual exercise as the answers
to these questions may lead to invaluable thera-
peutic strategies to treat the currently incur-
able disease of advanced prostate cancer.
HISTORICAL PERSPECTIVE OF
CANCER METASTASIS
Metastasis is a multi-step process that
includes growth in a primary organ, neoangio-
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genesis, intravasation into and survival in cir-
culation, attachment to a distant target organ,
extravasation at that site, and growth of a
secondary neoplasm and, as such, appears to be
an inefficient process (Fig. 1). While organ-
specific localization of luciferase-labeled PC-
3 human prostate cancer cell line cells was
visualized by non-invasive imaging 15 min post-
intracardiac injection in immunocompromised
mice, no viable cells were detected 24 h later.
Despite this indication that most of the injected
cells were either dead or metabolically inactive,
skeletal and soft tissue micrometastases were
apparent on imaging several days later and
were confirmed histologically and radiographi-
cally weeks later [Rosol et al., 2003]. Similarly,
intravital videomicroscopy of various types
of cancer showed that only 2% of cancer cells
formed micrometastases [Luzzi et al., 1998;
Vargheseetal.,2002].Furthermore,99%ofthese
micrometastases failed to form larger tumors,
althoughnumeroussolitarycellsremaineddetec-
table in the tissue months after injection [Nau-
mov et al., 2001, 2002; MacDonald et al., 2002].
Stephen Paget [1889] was the first to present
an explanation for the non-random patterns of
cancer metastases. His ‘‘seed and soil’’ theory
proposed that there was something about me-
tastatic sites that promoted cancer cell growth
similar to the tendency of seeds to grow in
fertile soil, i.e., that factors in the environment
at a metastatic site contributed to the prolife-
ration of cancer cells there. Forty years later,
James Ewing [1928] presented a different view
Fig. 1. Steps in prostate cancer metastasis to bone. Successful metastasis is a multi-step process that
includes (1) growth and escape from a primary organ, (2) intravasation, (3) survival in circulation, (4)
chemoattraction and extravasation, (5) and growth in bone through (6) cross-talks with osteoblasts and
osteoclasts. These steps require the ability of cancer cells to adhere to and migrate across the surrounding
extracellular matrix (ECM), actions mediated by the integrins.
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proposing that cancer cells grew at a particular
site because they were directed to that site by
the direction of blood flow and lymphatics. It is
likely that both of these theories are correct, at
least in part. Ewing’s theory accounts for cancer
growth in the draining lymph nodes and the
liver, but Paget’s theory describes distal metas-
tases that are organ-specific, such as metas-
tases to the bone.
Isaiah Fidler [2002] redefined the modern
‘‘seed and soil’’ hypothesis as three principles.
First, cancerous tissues contained heteroge-
neous subpopulations of cells with different
angiogenic, invasive, and metastatic properties.
Second, the metastatic process was selective for
cells that survived the long journey to a distal
organ. Finally, the success of the metastatic
cells depended on the ability of those cells to
interact and to utilize the ‘‘soil’’ provided in their
new microenvironment. These properties are
demonstrated by co-culture of an isolated mouse
femur with PC-3 human prostate cancer cells
(Fig. 2). As shown by scanning electron micro-
graph, after 3 days cells exhibiting diverse
phenotypes are attached to the bone. We hy-
pothesize that these variable morphologies may
represent the heterogeneous population of
prostate cancer cells that differentially res-
ponds to growth on bone. Alternatively, these
pleomorphic cells may be in different stages of
metastasis, as some appear anchored to the
bone at the extended edges, perhaps ‘‘feeling’’
out the environment for chemotactic factors,
while others seem to have formed firm adhe-
sions with the bone, suggesting that they may
have begun an invasive process.
METASTATIC PROCESS AND INTEGRINS
In normal prostate development, the interac-
tion of prostate epithelial cells with surround-
ing stroma influences their growth, survival,
and differentiation potential. Components of
the surrounding stroma include numerous cell
types, such as fibroblast, endothelial, neuroen-
docrine, and inflammatory cells; soluble growth
factors; and insoluble laminin-rich extracellu-
lar matrix (ECM). Many of the steps in cancer
metastasis involve changes in cell adhesion to
adjacent cells and to the ECM. The cell surface
receptor integrins have been implicated in
these events since they mediate homotypic and
heterotypic interactions of prostate cancer cells
within their microenvironment. Integrins are
composed of non-covalently associated a and b
subunits that play a role in mediating both cell–
cell interaction and cell–matrix interaction
(Fig. 3). To date, genes for 16 a and 8 b subunits
have been identified. Both types of subunits
encode single-pass transmembrane proteins
with short cytoplasmic tails, except for the b4
subunit which contains more than 100 residues
[Longhurst and Jennings, 1998; Mizejewski,
Fig. 2. Adhesion and invasion of PC-3 cells into mouse bone in
anexplantmodel. Several different cellmorphologies are evident
when PC-3 cells were co-cultured on mouse bone explant for
3 days, fixed with 2.5% glutaraldehyde in Sorenson’s buffer and
prepared for scanning electron microscopy. These cells possibly
represent either a heterogeneous population of prostate cancer
cells or cells in different stages of bone metastasis. Some cells
are elongated on the bone, perhaps in search of chemotactic
factors (arrows). Other cells exhibit halo-like area around
themselves, suggesting that they have initiated the invasion
process (arrowheads).
Fig. 3. Overview of the integrin signaling pathway at the focal
adhesion.Modulation of the integrins throughRhoGTPases leads
to changes in cell motility (see text for details). Activation of the
G-protein protease-activated receptor 1 (PAR1) by thrombin
receptor-activating pepetide (TRAP) is shown as an example in
moremotile (fibroblastoid) cells, Cdc42 regulates filopodia form-
ation to allow direction sensing of chemotaxis upon stimulation.
Once the direction has been established, Rac activity leads to
lamellipodium extension and new focal adhesions in the direc-
tion of the gradient. Increased activation of Rac and Cdc42 leads
to the down-regulation of the Rho signaling pathway that
regulates stress fiber formation, but activates contractile ring
formation, leading to cell migration. In less motile (epitheloid)
cells, cross-talks among the RhoGTPases lead to stress fiber
formation in the cell, thereby inducing cell spreading and
formation of high affinity integrin binding. Panel A: Represents a
scanning electron micrgraph of untreated control PC-3 cells
cultured on Thermanox coverslips. Panel B: Represents PC-3
cells 1 h after treatment with 10 mM TRAP to activate the
thrombin receptor, which leads to membrane ruffling and
filopodium extensions (Adapted from [Evers et al., 2000]).
708 Tantivejkul et al.
Fig. 3.
Prostate Cancer Bone Metastasis 709
1999]. The a subunits contain Ca2þ-binding
sites on the extracellular domain linked by a
disulfide bond to the transmembrane portion
[Argraves et al., 1987]. The b subunits contain
four repeating units of cysteine-rich motifs
proximal to the transmembrane region which
are joined together by disulfide bonds [Argraves
et al., 1987]. At least 22 different a/b hetero-
dimers are known, and it is the particular com-
bination of a and b subunits that determines
ligand binding specificity. For example, fibro-
nectin uniquely binds to the integrin hetero-
dimer of a5 and b1 [Argraves et al., 1987].
ESCAPE FROM THE PRIMARY TUMOR SITE
Changes in integrin expression have been
documented in primary prostate tumors and
prostate cancer cell lines compared to normal
prostate tissue (see Table I). Immunohis-
tochemical studies of normal, prostatic intrae-
pithelial neoplasia (PIN), and cancerous
prostate tissues indicate that loss of the laminin
receptor a6b4 integrins occurs with increasing
malignancy [Davis et al., 2001]. Low Gleason
sum score correlates with increased expression
of the a3 and a6 integrin subunits, while high
Gleason sum score correlates with low expres-
sion of a3 and negative expression of a6 integrin
subunits compared to normal prostate tissue
[Schmelz et al., 2002]. Furthermore, b1c integ-
rin, an alternatively spliced variant of the b1
subunit abundantly expressed in normal pros-
tate gland, inhibits cell proliferation [Fornaro
et al., 1998] and is down-regulated in prostate
carcinoma [Fornaro et al., 1996]. These changes
in integrin expression are modulated upstream
by many different factors including hormones
and growth factors. For example, androgen-
independent PC-3 prostate cancer cells trans-
fected with androgen receptor (AR) express
lower cell surface a6b4 integrins than the
parental cells [Bonaccorsi et al., 2000]. Further-
more, these AR-positive cells exhibit decreased
invasion through Matrigel, a laminin-rich
reconstituted basement membrane, and less
adhesion to laminin, thereby correlating
reduced expression of a6b4 integrins with
decreased invasiveness. Similarly, over expres-
sion of parathyroid hormone-related protein in
PC-3 cells increases cell surface integrin expres-
sion and leads to an increase in cell adhesion to
ECM proteins [Shen and Falzon, 2003].
The influence of integrin cell surface expres-
sion and interaction with the ECM in early
prostate cancer progression is also illustrated
by prostate acinar morphogenesis using a series
of human prostatic epithelial cell lines. Non-
tumorigenic RWPE-1 prostate epithelial cell
line form acini when grown in three-dimen-
sional Matrigel cell cultures, while invasive
WPE1-NB26 cells fail to form acini. In addition,
RWPE-1 cells form acini on laminin-1, but not
collagen or fibronectin, and are unable to form
these structures when exposed to blocking
antibodies for laminin-1 and laminin integrin
receptor a6 or b1 subunits [Bello-DeOcampo
et al., 2001a]. WPE1-NB26 cells show a lack of
a6 integrin expression as well as abnormal b1
integrin expression [Bello-DeOcampo et al.,
2001b]. Thus, alterations in the expression of
laminin integrin receptors correlate with the
ability of prostate cancer cells to escape the
laminin-rich ECM support at a primary tumor
site. This is further illustrated by the ability to
accelerate rates of tumor growth in immuno-
compromised mice injected with prostate cancer
cells suspended in Matrigel, which is abrogated




Primary tumor a6b4 Laminin Acinar morphogenesis [Mercurio et al., 2001;
Bello-DeOcampo et al., 2001b]a6b1 Laminin Migration, invasion
Circulatory system aIIbbIIIa Fibrinogen, platelets Microembolism, arrest
in circulation
[Trikha et al., 1998]
avb3 Vitronectin,
endothelial cells
Arrest in circulation [Romanov and Goligorsky, 1999;
Pilch et al., 2002]
Bone a2b1 Collagen Growth stimulation [Zheng et al., 2000; Kiefer
and Farach-Carson, 2001]a3b1 Collagen Migration, invasion
avb3 Osteopontin, osteonectin Growth stimulation,
migration, invasion
[Festuccia et al., 1999a;
Angelucci et al., 2002]
*The major contributory role of integrin-mediated cell adhesion in prostate cancer metastasis is summarized. Although each integrin
receptor can bind to multiple ligands and some ligand has multiple integrin receptors, only the contents of the ECM that are important
in prostate cancer progression are listed.
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by the inclusion of laminin cell adhesion peptide
YIGSR [Passaniti et al., 1992]. Secretion of
proteolytic enzymes by prostate cancer cells
permits the cells to digest through the basement
membrane to reach the microvasculature.
Laminin-5 is a crucial protein in mediating cell
stability, migration, and anchoring filament
formation. Invasive prostate carcinoma shows
a lack of protein expression of b3 and g2 chains
of laminin-5 and altered expression of the a3
chain [Hao et al., 2001]. Cleavage of laminin-5
by membrane-type 1 matrix metalloproteinase
enhances migration of DU145 prostate carci-
noma cells by two-fold compared to migration
on uncleaved Laminin-5 thus promoting the
escape of prostate cancer cells from the primary
site [Udayakumar et al., 2003].
SURVIVAL IN THE CIRCULATORY SYSTEM
After prostate cancer cells cross the surround-
ing stroma, they enter the microvasculature in a
process called intravasation and must evade
assault by the immune system and the simple
shear forces of blood flow. Cells appear to travel
through the blood as part of a fibrin clot sur-
rounded by other cancer cells and platelets to
survive [Walz and Fenton, 1994], with platelets
binding to cancer cells via the integrins aIIb-
bIIIa. Treatment with either anti-platelet anti-
bodies or heparin inhibits platelet-tumor cell
interaction [Borsig et al., 2001] and reduces
lung metastasis [Stoelcker et al., 1996]. Simi-
larly, blocking antibodies to aIIbbIIIa inhibits
lung colonization of mouse tail vein-injected
DU145 cells [Trikha et al., 1998].
In the vasculature, thrombin may mediate
cancer cell–platelet adhesion [Cooper et al.,
2003] and may activate resting platelet integ-
rins aIIbbIIIa to induce platelet aggregation
[Trikha and Nakada, 2002]. As well, activa-
tion of protease-activated receptor 1 (PAR1) on
cancer cells by thrombin increases cell adhesion
to platelets [Walz and Fenton, 1994]. Further-
more, we have previously shown that VCaP and
PC-3 prostate cancer cell lines, both derived
from osseous metastases, have increased PAR1
expression compared to normal prostate tissue
[Chay et al., 2002]. Thus the ability of cancer
cells to adhere and aggregate with platelets
through the expression of cell surface receptors
may protect them from shear stresses of the
circulation and facilitate arrest in the micro-
vasculature.
INTERACTION WITH THE ENDOTHELIUM
Hemodynamics may bring cancer cells into
the bone marrow, but it alone does not explain
the high frequency of prostate cancer metasta-
sis to the bone [Yoneda, 1998]. Perhaps the
presence of chemotactic gradients in the bone
sinusoids contributes to the attraction, but
the role cell–cell interaction plays cannot be
ignored. We have shown that prostate cancer
cells preferentially bind to bone marrow endo-
thelial cells three- to five-fold more than to
aortic, umbilical vein, or dermal vascular endo-
thelial cells [Lehr and Pienta, 1998; Cooper
et al., 2000b]. Furthermore, prostate cancer
cells adhere preferentially directly to these bone
endothelial cells and not to ECM proteins pre-
sent in the bone in vitro, although the growth of
bone marrow endothelial cells on bone ECM
components significantly increases their affi-
nity for PC-3 cells [Cooper et al., 2000b].
Adhesion and extravasation of prostate can-
cer cells from fenestrated bone marrow endothe-
lium most likely occurs as a complex set of
interactions between bone marrow endothelial
cells, bone ECM components, and bone marrow
stromal cells. The ‘‘dock and lock’’ mechanism
was proposed as one explanation for extravasa-
tion and is similar to the inflammatory response
of leukocytes [Honn and Tang, 1992] as both
processes involve the arrest of circulating cells
on the endothelium by low-affinity binding,
induction of a firmer cell adhesion, extravasa-
tion, and invasion of the surrounding matrix
[Buck, 1995]. During the ‘‘docking’’ step of
inflammatory response, induced expression of
P-selectin, a type of cell adhesion molecule on
platelets, leukocytes, and endothelial cells, on
activated endothelial cells is responsible for the
low affinity binding of leukocytes to endothelial
cells [Meyer and Hart, 1998]. Similarly, inter-
action of P-selectin with its ligand sialyl Lewisx
carbohydrates is believed to cause the arrest of
cancer cells in complex with platelets and
leukocytes [Chopra et al., 1990; Bhatti et al.,
1996; Borsig et al., 2001]. Indeed, elevated
expression of sialyl Lewisx is detected at the
surface of cancer cells and correlates with poor
prognosis in prostate cancer [Martensson et al.,
1995], and antibodies against sialyl Lewisx
block adhesion of neutrophils and tumor cells
to endothelial cells and platelets [Geng et al.,
1990]. Furthermore, fewer lung metastasis and
slower tumor growth occur when colon cancer
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cells are implanted into P-selectin-deficient
mice [Kim et al., 1998]. In breast and prostate
cancer cells, adhesion to the microvascular
endothelium of metastasis-prone tissues is also
mediated in part by interactions between
cancer-associated Thomsen–Friedenreich (TF)
glycoantigen (Galb1-3GalNAc) presenting on
neoplastic cells and b-galactoside binding lectin
galectin-3 expressing on endothelium [Lehr and
Pienta, 1998; Ellerhorst et al., 1999; Glinsky
et al., 2000, 2001; Nangia-Makker et al., 2002;
Khaldoyanidi et al., 2003]. This adhesion is
abrogated by blocking antibodies to b-galacto-
side-binding lectin, galectin-3, or TF antigen
[Lehr and Pienta, 1998; Glinsky et al., 2003].
Similar to inflammatory response of leuko-
cytes, the ‘‘locking’’ of prostate cancer cells to
endothelial cells is facilitated through the com-
plex collaboration of integrins. We have pre-
viously reported that b1 integrin was not
involved in PC-3 prostate cancer cell–endothe-
lial cell adhesion [Cooper et al., 2000a]. How-
ever, a more recent study showed that blocking
antibodies to this subunit inhibited adhesion of
PC-3 cells to bone marrow endothelial cells by
64% [Scott et al., 2001]. These conflicting results
suggest the involvement of other integrins or
cell adhesion molecules in prostate cancer cell
adhesion to the endothelium. Indeed, coopera-
tivity between avb3, a5b1 and a3b1 integrins is
necessary for PC-3 and DU145 cell adhesion to
interleukin-1-stimulated human umbilical vein
endothelial cells [Romanov and Goligorsky,
1999].
BONE MICROENVIRONMENT
Once cancer cells have reached the bone,
they must utilize the bone microenvironment to
survive and propagate. In a review of bone scans
from 27 patients with limited skeletal involve-
ment, the distribution pattern of early prostate
cancer metastases was similar to the distribu-
tion of normal adult bone marrow [Imbriaco
et al., 1998]. This observation supports Ewing’s
theory that cancer cell delivery to the bone is
simply a reflection of the volume of blood flow
[Ewing, 1928]. However, theories of preferen-
tial adhesion and the potential role of chemo-
attractants in colonization and subsequent
growth are not discounted [Keller et al., 2001;
Taichman et al., 2002; Cooper et al., 2003] as
there is little doubt that the bone microenviron-
ment provides a rich ‘‘soil’’ for the prostate
cancer cell ‘‘seeds’’ [Paget, 1889]. For example,
bone extracts induce at least a three-fold
increase in invasion by PC-3 and DU145 cells
compared with brain and other tissue extracts,
demonstrating that bone contains significant
migration and chemoinvasion promoting fac-
tors for prostate cancer cells [Jacob et al., 1999].
By purifying the bone extract, osteonectin was
identified as the chemoattractant that promo-
ted prostate cancer cell invasion [Jacob et al.,
1999]. Blocking antibodies to the avb3 integrins
have been shown to reduce prostate cancer cell
adhesion to crude bone protein extract by 94%
[Hullinger et al., 1998], suggesting the impor-
tance of the integrins in the process.
Numerous other factors contribute to pros-
tate cancer cell proliferation in the bone, and
many are mediated through the engagement of
integrin receptors. Unlike prostate epithelial
associated ECM, the main component of bone
ECM is collagen type I which is a ligand for a2b1
and a3b1 integrins. Greater proliferation rates
for prostate cancer cells are observed in cells
grown on collagen I compared to plastic or fibro-
nectin substrates; cell signaling through phos-
phatidylinositol 3-kinase (PI3K) and increased
expression of cyclin D1 are implicated in this
process [Kiefer and Farach-Carson, 2001].
Interestingly, osteopontin, a non-collagenous
bone ECM component, stimulates proliferation
of quiescent prostate epithelial cells more than
collagen in an integrin-mediated manner [Elga-
vish et al., 1998], stimulates anchorage-inde-
pendent growth of the human prostate cancer
cell lines LNCaP and C4-2 [Thalmann et al.,
1999], and induces PC-3 cell migration and
invasion via avb3 integrin function [Angelucci
et al., 2002].
Although more than 95% of the bone ECM is
composed of collagen type I, other proteins are
also deposited by osteoblasts during bone for-
mation [Hauschka et al., 1986]. Co-culture of
PC-3 cells with osteoblasts reveals that trans-
forming growth factor-b1 (TGF-b) produced by
osteoblasts stimulates PC-3 cell migration and
invasion as well as increases a2b1 and a3b1
integrins expressions [Festuccia et al., 1999a].
Furthermore, osteoblast-conditioned medium
stimulates the release of proteolytic enzymes
urokinase plasminogen activator and matrix
metalloproteinase-9 from prostate cancer cells
[Festuccia et al., 1999b].
Although factors in the bone microenviron-
ment promote prostate cancer cell growth,
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prostate cancer cells also contribute to bone
remodeling in a ‘‘vicious cycle’’ [Chung, 2003].
Because prostate cancer metastases are usually
osteoblastic in nature, the role of bone morpho-
genetic proteins (BMPs) in the course of bone
metastasis is quite intriguing since they con-
tribute to bone formation. Bentley et al. [1992]
first reported that the expression of BMP-6, a
member of the TGF-b superfamily, was detected
in prostate tissue samples of over 50% of
patients with clinically defined metastatic pros-
tate cancer, but not non-metastatic or benign
prostate samples. Subsequent studies have
confirmed the increased expression of BMP-6
in metastatic prostate cancer cells [Barnes etal.,
1995; Hamdy et al., 1997; Autzen et al., 1998;
Thomas and Hamdy, 2000]. It is believed that
secretion of BMP-6, among other proteins, by
prostate cancer cells contributes to osteoblastic
lesions because BMP-6 stimulates osteoblastic
differentiation of pluripotent mesenchymal
[Ebisawa et al., 1999]. Furthermore, osteoblas-
tic differentiation requires the activation of
focal adhesion kinase (FAK), an immediate
effector of the integrin signaling pathway
[Tamura et al., 2001].
INTEGRIN REGULATION OF MOTILITY AND
DYNAMIC CELL–SUBSTRATE INTERACTIONS
As discussed above, many steps of the meta-
static cascade involve the establishment and
termination of adhesive interactions between
cancer cells and the ECM via integrins. How-
ever, integrins also regulate intracellular
signaling pathways that control cytoskeletal
organization, force generation, and survival
[Hood and Cheresh, 2002]. This signal trans-
duction is modulated in two directions: activa-
tion of integrins to bind to ligands produces
‘‘inside-out’’ signaling and generation of ligand
bound integrins activates downstream intracel-
lular kinases and GTPases causing ‘‘outside-in’’
signaling. In this ‘‘outside-in’’ signaling, ligand
bound integrins cluster with structural and
catalytic focal adhesion-associated proteins at
cell–ECM junctions called focal adhesions.
Because integrins do not possess kinase activ-
ity, the focal adhesion-associated protein FAK
initiates the intracellular signaling cascade
using its ability to recruit downstream effectors
to the focal adhesion [Hood and Cheresh, 2002].
In prostate cancer, the highly tumorigenic PC-3
and DU145 cell lines have increased expression
of FAK compared to the poorly tumorigenic
LNCaP cells, suggesting a differential modula-
tion of the integrin signaling pathway in
metastatic prostate cancer cells [Slack et al.,
2001].
Cell motility are a coordination of focal
adhesion assembly at the leading edge of motile
cells, providing traction for cell migration, and
focal adhesion disassembly at the trailing edge
of these cells, resulting in forward movement
[Sastry and Burridge, 2000]. RhoGTPases,
activated through integrin-mediated, focal
adhesion-localized FAK and other tyrosine
kinases, and G-protein receptors, appear to be
key facilitators of these dynamics. These pro-
teins and their associated downstream signals
are elevated in malignant tissues but are almost
non-existent in normal tissues and benign
hyperplasias [Fritz et al., 2002; Kamai et al.,
2002; Kostenuik et al., 1996].
Currently there are at least 18 known mem-
bers of RhoGTPases. The best-characterized are
Cdc42, Rac, and Rho [Sahai and Marshall,
2002]. Activated Cdc42 produces filopodia,
actin-rich spikes that establish cell polarity by
sensing tactic signals [Arthur and Burridge,
2001]. These extended antennae allow cells to
detect changes in their surrounding and trans-
duce intracellular signals to adjust to their
microenvironment, a property which is crucial
in cancer metastasis. Activated Rac coordinates
focal adhesion assembly in lamellipodium and
membrane ruffling [Ridley et al., 1992; Nobes
and Hall, 1995; Clark et al., 1998]. These new
focal adhesions establish a path for cancer cells
to begin their quest to find more enriched ‘‘soil.’’
Activated Rho generates contractile forces that
push a cell body toward the leading edge and can
stimulate other downstream signaling path-
ways leading to stress fiber formation, cell
contraction, or actin polymerization depending
on cross-talk between Rac, Cdc42, and other
Rho regulatory proteins [Ridley, 2001]. For
example, inhibition of Rho kinase, a Rho down-
stream target, decreases prostate cancer cell
chemotactic migration in vitro and tumor
growth and angiogenesis in vivo [Somlyo et al.,
2000, 2003]. As well, a putative Rho regulatory
protein was recently identified that encodes
a novel Src homology 3 domain-containing
guanine nucleotide exchange factor (CSGEF)
[Qi et al., 2003]. Expressed only in prostate
and liver tissues, CSGEF mRNA levels are in-
creased two-fold in the LNCaP prostate cancer
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cell line after androgen treatment, suggesting
a possible role of CSGEF in modulating pros-
tate cancer cell metastasis. G-protein receptor
PAR1 activation of Rho similarly induces
actin cytoskeletal reorganization (reviewed in
[Whitehead et al., 2001]). In prostate cancer
cells, this activation contributes to increased
prostate cancer invasiveness [Chay et al., 2002;
Cooper et al., 2003; Greenberg et al., 2003] and
increased production of stress fibers in LNCaP
cells treated with thrombin [Greenberg et al.,
2003].
PROSPECT: CAN INTEGRINS BE USED
AS TARGETS TO PREVENT OR TREAT
BONE METASTASES?
Prostate cancer cells with varying degrees
of malignancy exhibit differential expression of
integrin receptors which leads to the ability of
these cells to develop preferential binding or
‘‘sensing’’ of the microenvironment through
different integrins [Edlund et al., 2001]. This
raises questions to the importance of integrins
in prostate cancer bone metastasis and to
their feasibility as therapeutic targets. Unfor-
tunately, the exact integrins involved in the
various steps of prostate cancer metastasis
remain undefined (See Table I). Furthermore,
the signaling pathways responsible for the
regulation of the cell surface expression of
integrins are unclear. For example, will inhibit-
ing the ‘‘sensing’’ mechanism of the cancer cells
through inhibition of the Cdc42 signaling path-
way be sufficient to suppress metastasis? Or is
there other mechanism(s) at work? The affinity
and avidity of the integrin receptors can be
modulated by many factors both from the
outside and the inside of cells. Weakly attached
cells cannot generate enough force for move-
ment whereas highly adhesive forces can render
cell immobility. We know that the ECM protein
substrates regulate the affinity of the integrins,
but what factors are regulating the avidity of
the integrins? Zheng et al. [2000] have shown
that LNCaP cells use the avb3 integrins to
adhere tovitronectinandosteopontin. However,
avb3 mediated cell migration and PI3K activa-
tion, through its downstream serine/threonine
kinase Akt, upon interaction with vitronectin,
whereas adhesion to osteopontin did not induce
avb3-mediated cell migration and PI3K/AKT
pathway activation, thus suggesting some un-
known mechanism co-modulating the ‘‘outside-
in’’ signaling pathway. Growth factors and
signaling through the G-protein-coupled recep-
tors have been known to activate RhoGTPases
(reviewed in [Kjoller and Hall, 1999]). Which
factor(s) in the microenvironments of the pri-
mary tumor, the circulation, and the target
organ can activate integrin-mediated adhesion,
dynamic cell structure, migration, and inva-
sion? The answers to these questions will lead
not only to a better understanding of the biology
of prostate cancer metastasis but should also
lead to the identification of therapeutic targets
for the prevention ant treatment of prostate
cancer metastasis.
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